Related Experiment Video
Updated: Dec 1, 2025

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
Clinical, inflammatory, and immune differences between COVID-19 patients with and without cancer: A protocol for
Zhongyang Yu1, Peipei Wang2, Bailin Chen3
1Oncology Department, Dongfang Hospital, Beijing University of Chinese Medicine, Fangguyuan Rd.
Introduction:
The World Health Organization announce that novel coronavirus (COVID-19) is pandemic worldwide on March 11, 2020. In this pandemic, cancer patients are prone to become critically ill after being infected with COVID-19 due to special immune conditions, and cannot effectively benefit from the treatment plan designed for normal people. However, only a few literatures report the differences between cancer patients and normal people after being infected with COVID-19. There is no systematic review to evaluate the clinical, inflammatory, and immune differences between COVID-19 patients with and without cancer. The systematic review aims to summarize and analyze the clinical, inflammatory, and immune differences between them.
Methods And Analysis:
We plan to conduct a systematic review according to the Preferred Reporting Items for Systematic Review and Meta-analysis Protocols (PRISMA-P) guidelines. Several databases (PubMed/MEDLINE, Embase, Web of Science, The Cochrane Library, CNKI, CBM, VIP, WanFang) were searched for relevant eligible observational studies on COVID-19 patients with cancer published from December 2019 to September 2020. Two researchers (Y.ZY and W.PP) will independently complete search strategy formulation, literature selecting, Information extraction, data collation, and quality assessment. The primary outcome will be the clinical characteristics differences between COVID-19 patients with and without cancer. Secondary outcomes will include immune function regulation characteristics such as T cell subset status, inflammation and other factors for COVID-19 patients with cancer. We intend to perform a meta-analysis of studies calculating odds ratio differences (Hedge g) for comparison in Forest plots and subgroup analysis after assessment of heterogeneity using I statistics based on compatibility on the basis of population and outcomes.
Ethics And Dissemination:
We will use the information from published researches with no need for ethical assessment. Our findings will be published in a peer-reviewed journal according to the PRISMA guidelines.
Prospero Registration Number:
CRD42020204417.
Related Concept Videos
Psychoneuroimmunology: Diabetes and Cancer
Cancer Survival Analysis
Tumor Immunotherapy
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

